[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Marmion et al., 1996 - Google Patents

Synthesis and characterization of novel N3O3-Schiff base complexes of 99gTc, and in vivo imaging studies with analogous 99mTc complexes

Marmion et al., 1996

Document ID
12683139969258924005
Author
Marmion M
Woulfe S
Newmann W
Pilcher G
Nosco D
Publication year
Publication venue
Nuclear medicine and biology

External Links

Snippet

Sixteen novel derivatives of 1, 1, 1-tris (salicylaldiminomethyl) ethane have been synthesized for the purpose of encapsulating 99mTc (IV) ions and generating new 99mTc radiopharmaceuticals. Two methods for the preparation of the 99gTc (IV) analog complexes …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0476—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic System
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
    • C07F15/0073—Rhodium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules

Similar Documents

Publication Publication Date Title
US4615876A (en) Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
Lever et al. Design, preparation, and biodistribution of a technetium-99m triaminedithiol complex to assess regional cerebral blood flow
Mastrostamatis et al. Tridentate ligands containing the SNS donor atom set as a novel backbone for the development of technetium brain-imaging agents
Duatti et al. Formation of the TcN multiple bond from the reaction of ammonium pertechnetate with S-methyl dithiocarbazate and its application to the preparation of technetium-99m radiopharmaceuticals
Tisato et al. Synthesis, characterization and electrochemical studies on technetium (V) and rhenium (V) oxo-complexes with N, N′-2-hydroxypropane-1, 3-bis (salicylideneimine)
Anderson et al. N, N′-ethylene-di-L-cysteine (EC) complexes of Ga (III) and In (III): molecular modeling, thermodynamic stability and in vivo studies
DE60127951T2 (en) SMALL TECHNETIUM 99M AND RHENIUM-MARKED MEANS AND METHOD FOR TUMOR IMAGING
DE69024038T2 (en) CORE FOR TECHNETIUM RADIO MEDICINAL PRODUCTS.
Marmion et al. Synthesis and characterization of novel N3O3-Schiff base complexes of 99gTc, and in vivo imaging studies with analogous 99mTc complexes
Smith et al. In vitro and in vivo characterization of novel water-soluble dithio-bisphosphine 99mTc complexes
WO2006080993A1 (en) Novel cationic metal complex radiopharmaceuticals
US4894445A (en) Metal-isonitrile adducts for preparing radionuclide complexes
US5693324A (en) Tris(isonitrile) copper(I) sulfates for preparing radionuclide complexes
Refosco et al. Synthesis and characterization of neutral technetium (III)-99 and-99m complexes with O, P-bidentate phosphino-carboxylate ligands. Crystal structure of mer-[Tc (O 2 CCH 2 CH 2 PPh 2) 3]· 2Me 2 SO
Li et al. Comparisons of 105Rh (III) chloride complexation with [14] aneNS3,[14] aneN2S2 and [14] aneN4 macrocycles in aqueous solution
Tsoukalas et al. Characterization and preliminary evaluation of ester-modified technetium-99m SNS/S mixed ligand complexes as potential brain perfusion agents
Pillai et al. Radiochemical studies of 99mTc complexes of modified cysteine ligands and bifunctional chelating agents
IL79602A (en) Method for preparing radionuclide complexed from metal-isonitrile adducts
Papadopoulos et al. Novel lipophilic amidate oxorhenium and oxotechnetium complexes as potential brain agents: synthesis, characterization and biological evaluation
Tsotakos et al. Benzimidazole derivatives as NSO ligands for the fac-[M (CO) 3]+(M= Re, 99mTc)
Lisic et al. 99mTc (LL) 3+ complexes containing ether analogs of DMPE
US5081232A (en) Complexes of tc99m radiopharmaceuticals
DE69831158T2 (en) HYDROXYMETHYL PHOSPHINE DERIVATIVES FOR USE AS DIAGNOSTIC AND THERAPEUTIC MEDICAMENTS AND THEIR METHODS
EP0419538A4 (en) Technetium (iii/ii) imaging agents
Cagnolini et al. Tetradentate bis-phosphine ligands (P2N2 and P2S2) and their Rh (III), Ni (II) and 105Rh Complexes: X-ray crystal structures of trans-[RhCl2 (L2)] PF6,[Ni (L2)](PF6) 2 and μ-O2SO2-[Ni (L5)] 2 (PF6) 2